DOP71: TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Saifuddin, A.(1)*;Madgwick, M.(2);Cozzetto, D.(1);Pavlidis, P.(3);Verstockt, B.(4,5);Hart, A.(1,6);Korcsmaros, T.(1);Powell, N.(1);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(3)King's College Hospital NHS Trust, Department of Gastroenterology, London, United Kingdom;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, United Kingdom;(6)St Mark's Academic Institute, Department of Gastroenterology, London, United Kingdom;
DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)ECCO’23 CopenhagenYear: 2023
Authors: Wong, E.C.L.(1);Dulai, P.S.(2);Marshall, J.K.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;
(1)McMaster University, Department of Medicine Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, Hamilton, Canada;(2)Northwestern University, Division of Gastroenterology, Chicago, United States;(3)Western University, Department of Medicine Division of Gastroenterology, London, Canada;(4)Medical University of Vienna, Department of Internal Medicine III Division of Gastroenterology and Hepatology, Vienna, Austria;
DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation ScaleECCO’23 CopenhagenYear: 2023
Authors: Takabayashi, K.(1)*;Kobayashi, T.(2);Matsuoka, K.(3);G Levesque, B.(4);Kawamura, T.(5);Tanaka, K.(5);Kadota, T.(6);Bise, R.(6);Uchida, S.(6);Kanai, T.(7);Ogata, H.(1);
(1)School of Medicine- Keio University, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology, Tokyo, Japan;(4)Los Angeles County/University of Southern California Medical Center, Division of Gastroenterology, Los Angeles, United States;(5)Kyoto Second Red Cross Hospital, Department of Gastroenterology, Kyoto, Japan;(6)Kyushu University, Department of Advanced Information Technology, Fukuoka, Japan;(7)School of Medicine- Keio University, Division of Gastroenterology and Hepatology Department of Internal Medicine, Tokyo, Japan;
DOP75: Video capsule endoscopy may detect active small bowel Crohn's disease requiring change of treatment despite unremarkable ileo-colonic anastomosisECCO’23 CopenhagenYear: 2023
Authors: Thurm, T.(1,2)*;Zmora, N.(1,2,3);Hirsh, A.(1,2);Deutsch, L.(1,2);Maharshak, N.(1,2);
(1)Tel-Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases, Tel-Aviv, Israel;(2)Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel;(3)Weizmann Institute of Science, Immunology Department, Rehovot, Israel;
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapyECCO’23 CopenhagenYear: 2023
Authors: Serclova, Z.(1)*;Tremerova, A.(2);Lengalova, M.(2);Petra, Z.(1);
(1)NH Hospital, Surgical Department, Horovice, Czech Republic;(2)NH Hospital, Surgical Departement, Horovice, Czech Republic;
DOP77: Is durable remission achievable after ileocolic resection for Crohn's disease ? Long-term results of a prospective multicentric cohort study of the GETAID ChirurgieECCO’23 CopenhagenYear: 2023
Authors: Abdalla, S.(1)*;Benoist, S.(1);Maggiori, L.(2);Lefevre, J.(3);Denost, Q.(4);Cotte, E.(5);Germain, A.(6);Beyer-Berjot, L.(7);Desfourneaux, V.(8);Rahili, A.(9);Duffas, J.P.(10);Pautrat, K.(11);Denet, C.(12);Bridoux, V.(13);Meurette, G.(14);Faucheron, J.L.(15);Loriau, J.(16);Souche, F.R.(17);Corte, H.(2);Zerbib, P.(18);Panis, Y.(19);Brouquet, A.(1);
(1)Le Kremlin-Bicetre University Hospital, Department of Digestive Surgery, Le Kremlin-Bicetre, France;(2)Saint-Louis University Hospital, Department of Digestive Surgery, Paris, France;(3)Saint-Antoine Hospital, Department of Digestive Surgery, Paris, France;(4)Bordeaux University Hospital, DEpartment of Digestive Surgery, Bordeaux, France;(5)Lyon-Sud University Hospital, Department of Digestive Surgery, Pierre-Benite, France;(6)Nancy University Hospital, Department of Digestive Surgery, Nancy, France;(7)Marseille University Hospital, Department of Digestive Surgery, Marseille, France;(8)Rennes University Hospital, Department of Digestive Surgery, Rennes, France;(9)Nice University Hospital, Department of Digestive Surgery, Nice, France;(10)Toulouse University Hospital, Department of Digestive Surgery, Toulouse, France;(11)Lariboisière University Hospital, Department of Digestive Surgery, Paris, France;(12)Institut Mutualiste Montsouris, Department of Digestive SUrgery, Paris, France;(13)Rouen University Hospital, Department of Digestive Surgery, Rouen, France;(14)Nantes University Hospital, Department of Digestive Surgery, Nantes, France;(15)Grenoble University Hospital, Department of Digestive Surgery, Grenoble, France;(16)Saint-Joseph Hospital, Department of Digestive Surgery, Paris, France;(17)Montpellier University Hospital, Department of Digestive Surgery, Montpellier, France;(18)Lille University Hospital, Department of Digestive Surgery, Lille, France;(19)Beaujon University Hospital, Department of Digestive Surgery, Clichy, France;GETAID Chirurgie
DOP78: Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).ECCO’23 CopenhagenYear: 2023
Authors: Alibert, L.(1);Betton, L.(2);Falcoz, A.(3);Manceau, G.(4);Benoist, S.(5);Zerbib, P.(6);Podevin, J.(7);Maggiori, L.(8);Brouquet, A.(5);Tyrode, G.(9);Vuitton, L.(9);Vernerey, D.(3);Lefevre, J.(2);Lakkis, Z.(1)*;
(1)University Hospital of Besançon, Department of Digestive Surgery, Besançon, France;(2)St Antoine Hospital, Department of Digestive Surgery, Paris, France;(3)University Hospital of Besançon, Methodology and Quality of Life Unit in Oncology, Besançon, France;(4)European Georges Pompidou Hospital, Department of Digestive and Oncologic Surgery, Paris, France;(5)Bicêtre Hospital, Department of Digestive Surgery and Surgical Oncology, Le Kremlin Bicêtre, France;(6)Lille University Hospital, Department of Digestive Surgery and Transplantation, Lille, France;(7)University Hospital of Nantes, Digestive and Endocrine Surgery Clinic, Nantes, France;(8)St Louis Hospital, Department of General- Endocrine and Digestive Surgery, Paris, France;(9)University Hospital of Besançon, Department of Gastroenterology, Besançon, France;GETAID Chirurgie
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scoresECCO’23 CopenhagenYear: 2023
Authors: Mateos, B.(1)*;Gaite, A.(1);Rodríguez-Lago, I.(2);M. Marigorta, U.(1);
(1)cic bioGUNE, Integrative Genomics, Bilbao, Spain;(2)Galdakao Hospital, Gastroenterology, Bilbao, Spain;
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Lawal, O.(1)*;Rodriguez-Sosa, A.(1);McDonnell, C.(1);Grant, L.(1);O'Brien, J.(2);Kel, A.(3);Dominik, A.(4);Stack, R.(5);Yochum, G.(6,7);Koltun, W.(6);Doherty, G.(5);Hussey, S.(8);
(1)Royal College of Surgeons in Ireland, School of Pharmacy and Biomolecular Sciences, Dublin, Ireland;(2)Children's Health Ireland- Crumlin, Department of Pathology, Dublin, Ireland;(3)GeneXplain GmbH, GeneXplain GmbH, Wolfenbüttel, Germany;(4)Children's Health Ireland- Crumlin, DOCHAS Study, Dublin, Ireland;(5)St. Vincent's University Hospital and University College, Center for Colorectal Disease, Dublin, Ireland;(6)The Pennsylvania State University- College of Medicine- PA, Department of Surgery- Division of Colon and Rectal Surgery, Pennsylvania, United States;(7)The Pennsylvania State University- College of Medicine- PA, Department of Biochemistry & Molecular Biology, Pennsylvania, United States;(8)UCD and Royal College of Surgeons in Ireland, Department of Paediatrics, Dublin, Ireland;
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapyECCO’23 CopenhagenYear: 2023
Authors: Lee, H.S.(1)*;Lee, Y.(1);Baek, J.(1);Kim, Y.(1);Park, S.(1);Jung, S.(1);Kim, K.K.(2);Hwang, S.W.(2);Lee, J.L.(3);Park, S.H.(2);Yang, S.K.(2);Han, B.(4);Song, K.(1);Yoon, Y.S.(3);Ye, B.D.(2);
(1)University of Ulsan College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology, Seoul, Korea- Republic Of;(3)University of Ulsan College of Medicine- Asan Medical Center, Department of Surgery, Seoul, Korea- Republic Of;(4)Seoul National University College of Medicine, Department of Biomedical Sciences, Seoul, Korea- Republic Of;
DOP82: Biological Treatment Cycles in Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Noor, N.(1)*;Sousa, P.(2);Bettenworth, D.(3);Gomollon, F.(4);Lobaton, T.(5,6);Bossuyt, P.(7);Casanova, M.J.(8);Ding, N.(9);Dragoni, G.(10,11);Furfaro, F.(12);van Rheenen, P.(13);Chaparro, M.(8);Gisbert, J.(8);Louis, E.(14);Papamichael, K.(15);
(1)Addenbrooke's Hospital- Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;(2)Viseu Unit- Tondela-Viseu Hospital Centre, Department of Gastroenterology, Viseu, Portugal;(3)University of Münster, Medical Faculty of the University of Münster, Münster, Germany;(4)Hospital Clínico Universitario Lozano Blesa, Department of Gastroenterology, Zaragoza, Spain;(5)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(6)Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium;(7)Imelda GI Clinical Research Centre, Department of Gastroenterology, Bonheiden, Belgium;(8)Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit- Hospital Universitario de La Princesa, Madrid, Spain;(9)University of Melbourne- St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(10)University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio'- Gastroenterology Research Unit, Florence, Italy;(11)Careggi University Hospital, IBD Referral Center- Gastroenterology Department, Florence, Italy;(12)IRCCS San Raffaele Hospital, Department of Gastroenterology and Endoscopy, Milan, Italy;(13)University Medical Center Groningen, Department of Paediatric Gastroenterology, Groningen, The Netherlands;(14)Liege University Hospital- CHU Liege, Department of Hepato-Gastroenterology and Digestive Oncology, Liege, Belgium;(15)Beth-Israel Deaconess Medical Center- Harvard Medical School, Center for Inflammatory Bowel Diseases- Division of Gastroenterology, Boston, United States;
DOP83: Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn's disease receiving maintenance infliximab: A randomized controlled trialECCO’23 CopenhagenYear: 2023
Authors: Kang, B.(1)*;Moon, J.S.(2);Lee, Y.J.(3);Kim, M.J.(4);Choe, B.H.(1);Ko, J.S.(2);Park, J.H.(3);Choe, Y.H.(4);
(1)Kyungpook National University School of Medicine, Department of Pediatrics, Daegu, Korea- Republic Of;(2)Seoul National University College of Medicine, Department of Pediatrics, Seoul, Korea- Republic Of;(3)Pusan National University College of Medicine, Department of Pediatrics, Yangsan, Korea- Republic Of;(4)Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, Korea- Republic Of;
DOP84: IBD-related hospitalization and surgery rates in biologic-naïve patients with IBD treated with vedolizumab versus other biologics: Results from a long-term, prospective, observational studyECCO’23 CopenhagenYear: 2023
Authors: Sebastian, S.(1)*;Siegel, C.(2);Siegmund, B.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
(1)Hull University Teaching Hospital, IBD Unit, Hull, United Kingdom;(2)Dartmouth Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, United States;(3)Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany;(4)Takeda, Gastroenterology, Cambridge- MA, United States;(5)Takeda, Gastroenterology, Zurich, Switzerland;(6)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;
DOP85: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial.ECCO’23 CopenhagenYear: 2023
Authors: Schulberg, J.(1,2)*;Hamilton, A.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Lovett, G.(1,2);Sutherland, T.(2,3);Ross, A.(1);Vogrin, S.(2);Kamm, M.(1,2);
(1)St. Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St. Vincent's Hospital Melbourne, Department of Radiology, Melbourne, Australia;
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).ECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Hanauer, S.B.(2);Sandborn, W.(3);Sands, B.E.(4);Schreiber, S.(5);Danese, S.(6);Kierkus, J.(7);Kulynych, R.(8);Klopocka, M.(9);Lahat, A.(10);Gonciarz, M.(11);Osipenko, M.(12);Borzan, V.(13);Kowalski, M.(14);Saenko, D.(15);Sardinov, R.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Yang, S.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Park, G.(18);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Northwestern University/ Feinberg School of Medicine, Gastroenterology and Hepatology, Chicago- IL, United States;(3)University of California San Diego, Gastroenterology, La Jolla, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)University Hospital Schleswig Holstein, Medicine I, Kiel, Germany;(6)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(7)The Children Memorial Health Institute, Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(8)Zaporizhzhia regional clinical hospital, Gastroenterology and Endoscopy, Zaporizhzhia, Ukraine;(9)Nicolaus Copernicus University- Collegium Medicum in Bydgoszcz, Gastroenterology and Nutrition Disorders, Bydgoszcz, Poland;(10)Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;(11)Military Institute of Medicine - National Research Institute, Gastroenterology and Internal Diseases, Warsaw, Poland;(12)Novosibirsk Medical University, Novosibirsk Medical University, Novosibirsk, Russian Federation;(13)Clinical Hospital Center Osijek- Faculty of medicine Osijek, Gastroenterology, Osijek, Croatia;(14)Centrum Diagnostyczno – Lecznicze Barska, Gastroenterology, Wloclawek, Poland;(15)LLC "Clinica UZI 4D", LLC "Clinica UZI 4D", Pyatigorsk- Stavropol Region, Russian Federation;(16)BioTechService LLC- St. Petersburg Medical and Social Institute, Therapy, Saint-Petersburg, Russian Federation;(17)Celltrion- Inc., Medical Science Division, Incheon, Korea- Republic Of;(18)Celltrion- Inc., Data Science Institute, Incheon, Korea- Republic Of;CT-P13 SC 3.8
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study ResultsECCO’23 CopenhagenYear: 2023
Authors: Feagan , B.G.(1)*;Sands , B.(2);Siegel , C.A.(3);Dubinsky , M.(4);Longman , R.(5);Sabinho , J.(6);Laurent , O.(7);Luo , A.(7);Lu, JD.(7);Nguyen, D.(7);Towfic , F.(7);DuVall, A.(8);Woyranowski , M.(9);Al Kharrat , H.(10);McGovern, D.P.B.(11);
(1)Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada;(2)Icahn School of Medicine at Mount Sinai, New York, New York, USA;(3)Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire,USA;(4)Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA;(5)Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA;(6)Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium;(7)Prometheus Biosciences, Inc., San Diego, CA, USA;(8)Tyler Research Institute, LLC, Tyler, TX,USA;(9)Department of Pediatrics, Faculty of Medicine and Health Sciences, UJK Kielce, former IP CZD Warsaw, Poland;(10)West Texas Digestive Disease Center, Lubbock, Texas,USA;(11)Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA;
DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Lin, S.(1,2)*;Hannon, E.(3);Waring, J.F.(4);Reppell, M.(4);Smaoui, N.(4);Pivorunas, V.L.(4);Guay, H.(4);Chanchlani, N.(1,2);Bewshea, C.(2);Bai, B.Y.H.(5,6);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Mill, J.(3);Ahmad, T.(1,2);
(1)Royal Devon University Healthcare NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)University of Exeter, University of Exeter Medical School- College of Medicine and Health, Exeter, United Kingdom;(4)AbbVie Inc, Research and Development, Chicago, United States;(5)Wellcome Sanger Institute, Genomics of Inflammation and Immunity Group, Hinxton, United Kingdom;(6)University of Cambridge, Postgraduate School of Life Sciences, Cambridge, United Kingdom;
DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide studyECCO’23 CopenhagenYear: 2023
Authors: Fumery, M.(1)*;Nancey, S.(2);Nachury, M.(3);Allez, M.(4);Rouillon, C.(5);Boureille, A.(6);Altwegg, R.(7);Serrero, M.(8);Vuitton, L.(9);Bouguen, G.(10);Abitbol, V.(11);Boualit, M.(12);Biron, A.(13);Panis, Y.(14);Laharie, D.(15);Amiot, A.(16);Simon, M.(17);Caillo, L.(18);Hébuterne, X.(19);Vidon, M.(20);Benezech, A.(21);Elgharabawy , Y.(22);Peyrin-biroulet, L.(23);
(1)Amiens University Hospital, Gastroenterology, Amiens, France;(2)Lyon University Hospital, Gastroenterology, Lyon, France;(3)Lille University Hospital, Gastroenterology, Lille, France;(4)Saint Louis Hospital, Gastroenterology, Paris, France;(5)Caen University Hospital, Gastroenterology, Caen, France;(6)Nantes University Hospital, Gastroenterology, Nantes, France;(7)Montpellier University Hospital, Gastroenterology, Montpellier, France;(8)Marseille University Hospital, Gastroenterology, Marseille, France;(9)Besancon University Hospital, Gastroenterology, Besancon, France;(10)Rennes University Hospital, Gastroenterology, Rennes, France;(11)Cochin Hospital, Gastroenterology, Paris, France;(12)Valenciennes Hospital, Gastroenterology, Valenciennes, France;(13)Reims University Hospital, Gastroenterology, Reims, France;(14)GH Privé Ambroise Paré-Hartmann, Colorectal surgery, Neuilly sur Seine, France;(15)Bordeaux University Hospital, Gastroenterology, Bordeaux, France;(16)Kremlin-Bicêtre Hospital, Gastroenterology, Kremlin-Bicêtre, France;(17)Institut Mutualiste Montsouris, Gastroenterology, Paris, France;(18)Nimes University Hospital, Gastroenterology, Nimes, France;(19)Nice University Hospital, Gastroenterology, Nice, France;(20)CHI Creteil, Gastroenterology, Creteil, France;(21)CH Avignon, Gastroenterology, Avignon, France;(22)GETAID, Getaid, Paris, France;(23)Nancy University Hospital, Gastroenterology, Nancy, France;GETAID
DOP90: The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumabECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Sapin, C.(2);Chan-Diehl, F.W.(3);Moses, R.E.(3);Siegmund, B.(4);Walsh, A.(5);Kobayashi, T.(6);Parambir, D.S.(7);Travis, S.(8);
(1)University of Calgary, Faculty of Medicine at the Cumming School of Medicine, Calgary, Canada;(2)Eli Lilly France, Rheumatology & Gastroenterology – Real World & Access Analytics RWA² Global Statistical Sciences & Advanced Analytics, Neuilly sur Seine, France;(3)Eli Lilly and Company, Gastroenterology, Indianapolis, United States;(4)Universitätsmedizin Berlin, Medizinische Klinik für Gastroenterologie- Infektiologie- Rheumatologie Charité, Berlin, Germany;(5)Nuffield Health- The Manor Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom;(6)Kitasato University -Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;(7)Feinberg School of Medicine Northwestern University, Gastroenterology and Hepatology, Chicago, United States;(8)Oxford University, Nuffield Department of Medicine, Oxford, United Kingdom;
